Catalyst Wire Dossier Catalyst Wire Dossier

ABP 654

adalimumab biosimilar · Amgen
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ABP 654, covering 2023-12-15 to 2024-01-11. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis [Phase 3]

See pricing